Docket No.: TRA-006.01

AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of the claims in the application.

Claims

- (Withdrawn) A composition comprising a liposome or lipid complex and an entrapped active platinum compound, the liposome or lipid complex containing one or more lipids, wherein the active platinum compound to lipid ratio is from 1:50 to 1:2 by weight.
- (Withdrawn) The composition of claim 1, wherein the active platinum compound to lipid ratio is from 1:50 to 1:5 by weight.
- (Withdrawn) The composition of claim 1, wherein the active platinum compound to lipid ratio is from 1:50 to 1:10 by weight.
- (Withdrawn) The composition of claim 1, wherein the active platinum compound is cisplatin.
- (Withdrawn) The composition of claim 1, wherein the active platinum compound to lipid ratio is from 1:25 to 1:15 by weight.
- (Withdrawn) The composition of claim 5, wherein the active platinum compound is cisplatin.
- 7. (Withdrawn) The composition of claim 6, the one or more lipids comprise DPPC.
- 8. (Withdrawn) The composition of claim 7, the one or more lipids comprise cholesterol.

- 9. (Withdrawn) The composition of claim 7, the one or more lipids comprise 50-100 [90?] mol% DPPC and 0-50 mol% cholesterol.
- 10. (Withdrawn) The composition of claim 7, the one or more lipids comprise 50-65 mol% DPPC and 35-50 mol% cholesterol
- 11. (Currently amended) A process for making a platinum aggregate comprising the steps of:
 - (a) combining an active platinum compound and a hydrophobic matrix carrying system;
 - (b) establishing the mixture at a first temperature; and
 - (c) thereafter establishing the mixture at a second temperature, which second temperature is cooler than the first temperature;

wherein the steps (b) and (c) are effective to increase the encapsulation of active platinum compound, wherein steps (b) and (c) are repeated for a total of two or more cycles.

- 12. (Canceled).
- 13. (Original) The process of claim 11, wherein the active platinum compound solution is produced by dissolving active platinum compound in a saline solution to form a platinum solution.
- 14. (Original) The process of claim 13, wherein the active platinum compound is cisplatin
- 15. (Original) The process of claim 11, wherein the hydrophobic matrix carrying system comprises liposome or lipid complex-forming lipids.
- 16. (Original) The process of claim 15, wherein the one or more lipids comprise DPPC.
- 17. (Original) The process of claim 15, wherein the one or more lipids further comprise cholesterol.

- 18. (Original) The process of claim 11, wherein the hydrophobic matrix carrying system is produced by dissolving one or more lipids in ethanol to form a lipid solution and injecting the lipid solution into an aqueous medium containing active platinum compound.
- 19. (Original) The process of claim 11, further comprising sequentially repeating the steps (b) and (c) for a total of three or more cycles.
- 20. (Original) The process of claim 19, wherein the step (c) comprises establishing the mixture at a temperature from -25 degrees Celsius to 25 degrees Celsius.
- 21. (Original) The process of claim 19, wherein step (c) comprises establishing the mixture at a temperature from -5 degree Celsius to 5 degrees Celsius.
- 22. (Original) The process of claim 19, wherein the step (b) comprises establishing the mixture at a temperature from 4 degrees Celsius to 75 degrees Celsius.
- 23. (Original) The process of claim 19, wherein the step (b) comprises establishing the mixture at a temperature from 45 degrees Celsius to 55 degrees Celsius.
- 24. (Original) The process of claim 11, wherein the temperature differential between steps (b) and (c) is 25 degrees Celsius or more.
- 25. (Original) The process of claim 24, wherein the temperature established in step (b) is 50 degrees Celsius or more.
- 26. (**Original**) The process of claim 11, wherein the temperature established in step (b) is 50 degrees Celsius or more.
- 27. (Original) A platinum aggregate produced by the method of claim 11.

- 28. (Original) A platinum aggregate produced by the method of claim 14.
- (Withdrawn) A pharmaceutical formulation comprising the composition of claim 1 and a
 pharmaceutically acceptable carrier or diluent.
- (Withdrawn) A pharmaceutical formulation comprising the composition of claim 1, adapted for inhalation by a patient.
- (Withdrawn) A pharmaceutical formulation comprising the composition of claim 1, adapted for injection into a patient.
- 32. (Original) The process of claim 11, further comprising, after all of steps (b) and steps (c) have been completed:
- (d) removing un-entrapped active platinum compound by filtering through a membrane having a molecular weight cut-off selected to retain desired liposomes or lipid complexes and adding a liposome or lipid complex compatible liquid to wash out un-entrapped active platinum compound.